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Supporting the education programs of Diabetes Australia
Type 2 diabetes:  
Goals for optimum 
management
The table on the reverse 
lists goals for optimum 
management that all 
people with type 2 
diabetes should be 
encouraged to reach.
This table has  
been specifically 
designed as a  
card for you to  
pull out and place  
on your desk or  
nearby for easy  
reference.
Type 2 diabetes: Goals for optimum management
Encourage all people with type 2 diabetes to approach/reach these goals
Diet Advise eating according to Australian dietary guidelines, with attention to 
quantity and type of food
If concerns are held regarding cardiovascular disease (CVD) risk, advise 
individual dietary review
Body mass index (BMI) Therapeutic goal is 5–10% weight loss for people who are overweight or 
obese with type 2 diabetes
Those with BMI >35 kg/m2 and comorbidities, or BMI >40 kg/m2, greater 
weight loss measures should be considered
Note that BMI is a difficult parameter to standardise between different 
population groups
Physical activity At least 30 minutes of moderate physical activity on most if not all days 
of the week (total ≥150 minutes/week)
Cigarette consumption 0 per day
Alcohol consumption Advise ≤2 standard drinks (20 g) per day for men and women
Blood glucose level (BGL) Advise 6–8 mmol/L fasting and 8–10 mmol/L postprandial
Ongoing self-monitoring of blood glucose is recommended for people 
with diabetes using insulin, people using sulphonylureas or other medicines 
that may cause hypoglycaemia, hyperglycaemia arising from illness, with 
haemoglobinopathies, pregnancy or other conditions where data on 
glycaemic patterns is required
Routine self-monitoring of blood glucose in low-risk patients who are 
using oral glucose-lowering drugs (with the exception of sulphonylureas) 
is not recommended
Glycated haemoglobin (HbA1c) Needs individualisation according to patient circumstances. Generally:
• ≤53 mmol/mol (48–58 mmol/mol)
• ≤7% (6.5–7.5%)
Allowing for normal variation in test accuracy, HbA1c results that range 
between 6.5% and 7.5% (48 and 58 mmol/mol) would reflect this goal.
Total cholesterol <4.0 mmol/L Initiation of pharmacotherapy is dependent on the assessment of absolute 
CVD risk (refer to the Australian absolute CVD risk calculator at www.
cvdcheck.org.au). This requires using multiple risk factors, which is 
considered more accurate than the use of individual parameters
Once therapy is initiated, the specified targets apply; however, these targets 
should be used as a guide to treatment and not as a mandatory target
High-density lipoprotein-
cholesterol (HDL-C) ≥1.0 mmol/L
Low-density lipoprotein-
cholesterol (LDL-C) <2.0 mmol/L
Non–HDL-C <2.5 mmol/L
Triglycerides <2.0 mmol/L
Blood pressure (BP)  
≤140/90 mmHg
Lower BP targets may be considered for younger people and for secondary 
prevention in those at high risk of stroke, as long as treatment burden does 
not increase risk
The target BP for people with diabetes and albuminuria/proteinuria remains 
<130/80 mmHg. As always, treatment targets should be individualised and 
monitored for side effects from medications used to lower BP
Urine albumin excretion Urine albumin-to-creatinine ratio (UACR):
• women: <3.5 mg/mmol
• men: <2.5 mg/mmol
Timed overnight collection: <20 mcg/min
Spot collection: <20 mg/L
Vaccination Consider immunisation against influenza and pneumococcal disease, 
and the diphtheria-tetanus-acellular pertussis (dTpa) vaccine
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About the RACGP
The RACGP is Australia’s largest professional general practice organisation and 
represents urban and rural general practitioners (GPs). We represent more than 
33,000 members working in or towards a career in general practice and are proud that 
more than 22,500 GPs in Australia have chosen to be a member of the RACGP.
The RACGP is responsible for defining the nature of the general practice discipline, 
setting the standards and curriculum for education and training, maintaining the 
standards for quality clinical practice, and supporting GPs in their pursuit of excellence 
in patient care and community service. We offer our members access to a vast suite 
of clinical resources, business support tools, education programs and are proud to 
advocate for the general practice profession on behalf of all GPs.
The RACGP advocates and promotes high-quality diabetes management and care 
through:
• regular articles in Australian Family Physician (AFP), the most widely read peer-
reviewed general practice journal in Australia, available at www.racgp.org.au/
publications/afp
• online general practice education provided by gplearning – the RACGP’s online 
learning portal
• advocacy on key issues related to diabetes management
• partnership with Diabetes Australia in the production of this handbook
• giving members access to an extensive library collection, with many items available 
electronically
• the flagship products Guidelines for preventive activities in general practice (Red 
Book), Putting prevention into practice: Guidelines for the implementation of 
prevention in the general practice setting (Green Book) and Smoking, nutrition, 
alcohol, physical activity (SNAP): A population health guide to behavioural risk 
factors in general practice, available at www.racgp.org.au/your-practice/guidelines
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About Diabetes Australia
Diabetes Australia is the national body for people affected by all types of diabetes 
and those at risk. We are committed to reducing the impact of diabetes.
Diabetes Australia combines the voice of consumers, health professionals 
and researchers dedicated to diabetes.
Diabetes Australia has four key activities:
• National leadership – National policy and advocacy, and raising of awareness 
of diabetes and its impact.
• Management of diabetes – Supporting and developing national self-management 
programs, and promoting the best possible management of diabetes to help 
prevent complications. These activities cover type 1, type 2 and gestational 
diabetes.
• Prevention – Supporting and developing prevention policies and programs for both 
the high-risk population (two million Australians at high risk) and the primary 
prevention at a whole-of-population level.
• Research – Supporting, funding and promoting the best diabetes research.
Diabetes Australia is the Australian member of the International Diabetes Federation 
(IDF), through which we work to reduce the impact of diabetes throughout the world, 
particularly in the Western Pacific region.
Working with general practice
Diabetes Australia publishes the Diabetes Management Journal quarterly, to inform 
GPs and health professionals in the field of diabetes management. This ensures 
that the latest information on the optimum care for people with diabetes, and the 
latest developments in diabetes management are delivered to frontline healthcare 
providers. The Diabetes Management Journal is available through Diabetes Australia, 
and professional membership of state and territory diabetes organisations at 
www.diabetesaustralia.com.au
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National Diabetes Services Scheme
Diabetes Australia administers the National Diabetes Services Scheme (NDSS) in 
conjunction with state and territory diabetes organisations. The NDSS is an Australian 
Government initiative and has operated successfully for more than 28 years. The 
NDSS provides universal access for all Australians with diabetes to subsidised 
diabetes products, and education and support services. As at December 2015, there 
were more than 1.2 million Australians registered with the NDSS.
Through the NDSS, people with diabetes can receive telephone support via the National 
Helpline 1300 136 588, along with a range of diabetes information and educational 
resources and programs targeted for type 1, type 2 and gestational diabetes.
Educational resources from Diabetes Australia
Membership of state and territory diabetes organisations provides access to a wide 
range of educational resources and support for people with diabetes, their families 
and carers. To find out more, visit www.diabetesaustralia.com.au and click on your 
state or territory.
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RACGP  The Royal Australian College of General Practitioners
RANZCOG  The Royal Australian and New Zealand College of Obstetricians 
and Gynaecologists
RBG  random blood glucose
RCPA The Royal College of Pathologists of Australasia
RCT randomised controlled trial
RR relative risk
RRR relative risk reduction
SAVOR-TIMI  Saxagliptin Assessment of Vascular Outcomes Recorded in Patients 
with Diabetes Mellitus Thrombolysis in Myocardial Infarction
SBP systolic blood pressure
SGLT2 sodium glucose co-transporter 2
SGLT2i sodium glucose co-transporter 2 inhibitor
SIGN  Scottish Intercollegiate Guidelines Network
SIP Service Incentive Payments
SMBG  Self-monitoring of blood glucose
SNAP  Smoking, nutrition, alcohol, physical activity
SOE statement of evidence
STOP-NIDDM Study to Prevent Non-Insulin-Dependant Diabetes Mellitus
SU sulphonylureas
TBI toe-brachial index
TCA team care arrangement
TECOS  Trial to Evaluate Cardiovascular Outcomes after Treatment  
with Sitagliptin
TGA  Therapeutic Goods Administration
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TZD thiazolidinedione
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UKPDS UK Prospective Diabetes Study
USPSTF US Preventive Services Task Force
WHO World Health Organization
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Summary, explanation and source of 
recommendations
The coding scheme for levels of evidence and grades of recommendation in this 
publication are provided in this summary. Refer to Section 1.3. How to use these 
guidelines for further explanation on how to use these recommendations.
National Health and Medical Research Council’s levels 
of evidence and grades of recommendation
Levels of evidence
Level Explanation
I Evidence obtained from a systematic review of level II studies
II Evidence obtained from a randomised controlled trial (RCT)
III-1 Evidence obtained from a pseudo-RCT (ie alternate allocation or some other method)
III-2 Evidence obtained from a comparative study with concurrent controls:
• non-randomised, experimental trial
• cohort study
• case-control study
• interrupted time series with a control group
III-3 Evidence obtained from a comparative study without concurrent controls:
• historical control study
• two or more single arm study
• interrupted time series without a parallel control group
IV Case series with either post-test or pre-test/post-test outcomes
Practice 
Point
Opinions of respected authorities, based on clinical experience, descriptive studies 
or reports of expert committees
Grades of recommendations
Grade Explanation
A Body of evidence can be trusted to guide practice
B Body of evidence can be trusted to guide practice in most situations
C Body of evidence provides some support for recommendation(s), but care should 
be taken in its application
D Body of evidence is weak and recommendation must be applied with caution
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Scottish Intercollegiate Guidelines Network’s levels of 
evidence and grades of recommendations (1999–2012)
Levels of evidence
Level Explanation
1++ High-quality meta-analyses, systematic reviews of randomised controlled trial (RCTs), 
or RCTs with a very low risk of bias
1+ Well-conducted meta-analyses, systematic reviews or RCTs with a low risk of bias
1– Meta-analyses, systematic reviews of RCTs or RCTs with a high risk of bias
2++ High-quality systematic reviews of case control or cohort or studies
High-quality case control or cohort studies with a very low risk of confounding or bias 
and a high probability that the relationship is causal
2+ Well-conducted case control or cohort studies with a low risk of confounding or bias 
and a moderate probability that the relationship is causal
2– Case control or cohort studies with a high risk of confounding bias or chance 
and significant risk that the relationship is not causal
3 Non-analytic studies (eg case reports, case series)
4 Expert opinion
Grades of recommendations
A At least one meta-analysis, systematic review, or RCT rated as 1++, and directly 
applicable to the target population; or
A body of evidence consisting principally of studies rated as 1+, directly applicable 
to the target population, and demonstrating overall consistency of results
B A body of evidence including studies rated as 2++, directly applicable to the target 
population, and demonstrating overall consistency of results; or
Extrapolated evidence from studies rated as 1++ or 1+
C A body of evidence including studies rated as 2+, directly applicable to the target 
population and demonstrating overall consistency of results; or
Extrapolated evidence from studies rated as 2++
D Evidence level 3 or 4; or
Extrapolated evidence from studies rated as 2+
Good 
practice 
points
Recommended best practice based on the clinical experience of the guideline 
development group
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American Diabetes Association’s levels of evidence
Levels of 
evidence
Explanation
A Clear evidence from well-conducted, generalisable randomised controlled trials (RCTs) 
that are adequately powered, including:
• evidence from a well-conducted multicenter trial
• evidence from a meta-analysis that incorporated quality ratings in the analysis
Compelling non-experimental evidence (ie ‘all or none’ rule developed by the Centre 
for Evidence-Based Medicine at the University of Oxford)
Supportive evidence from well-conducted RCTs that are adequately powered, including:
• evidence from a well-conducted trial at one or more institutions
• evidence from a meta-analysis that incorporated quality ratings in the analysis
B Supportive evidence from well-conducted cohort studies:
• evidence from a well-conducted prospective cohort study or registry
• evidence from a well-conducted meta-analysis of cohort studies
Supportive evidence from a well-conducted case-control study
C Supportive evidence from poorly controlled or uncontrolled studies:
• evidence from randomised clinical trials with one or more major or three or more 
minor methodological flaws that could invalidate the results
• evidence from observational studies with high potential for bias (such as case 
series with comparison with historical controls)
• evidence from case series or case reports
Conflicting evidence with the weight of evidence supporting the recommendation
E Expert consensus or clinical experience
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Summary of recommendations
Please note that the asterisk (*) that appears next to ‘Grade’ in the following 
recommendations are explained in Summary, explanation and source of 
recommendations.
3.1 Identifying risk of diabetes in asymptomatic 
patients
Recommendations Reference Grade*
Individuals should be screened for risk of diabetes every three 
years from 40 years of age using AUSDRISK
25
NHMRC, 2009
C
Individuals at high risk with any one of following risk factors:
 – AUSDRISK score of 12 or more
 – all people with a history of a previous cardiovascular event 
(acute myocardial infarction or stroke)
 – women with a history of gestational diabetes mellitus
 – women with polycystic ovary syndrome
 – patients on antipsychotic drugs
25
NHMRC, 2009
• should be screened with fasting blood glucose  
(or glycated haemoglobin [HbA1c])
• every three years
B
Individuals at high risk with impaired glucose tolerance test or 
fasting glucose (not limited by age) should be screened:
25
NHMRC, 2009
C
• with fasting blood glucose (or HbA1c)
• every 12 months
B
C
Risk assessment should begin from 18 years of age in Aboriginal 
and Torres Strait Islander peoples
25
NHMRC, 2009
Practice 
Point
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4. Preventing type 2 diabetes
Recommendations Reference Grade*
Lifestyle modifications that focus on increased physical activity, 
dietary change and weight loss should be offered to all individuals 
at high risk of developing type 2 diabetes
Structured diabetes prevention programs are available
42
NHMRC, 2009
A
Bariatric surgery can be considered in selected morbidly 
obese individuals (based on weight alone or the presence of 
comorbidities) who are at high risk of type 2 diabetes
42
NHMRC, 2009
C
Individuals who are at high risk of diabetes should be identified 
through the use of risk assessment tools
42
NHMRC, 2009
C
5.1 Patient-centred diabetes care
Recommendations Reference Grade*
A patient-centred communication style that incorporates patient 
preferences, assesses literacy and numeracy, and addresses 
cultural barriers to care should be used
19
American 
Diabetes 
Association, 2015
B
5.2 A structured diabetes care program consistent 
with the Chronic Care Model
Recommendations Reference Grade*
Care should be aligned with components of the Chronic Care 
Model (CCM) to ensure productive interactions between a prepared 
proactive practice team and an informed activated patient
56
American 
Diabetes 
Association, 2016
A
When feasible, care systems should support team-based care, 
community involvement, patient registries and embedded 
decision-support tools to meet patient needs
56
American 
Diabetes 
Association, 2016
B
Treatment decisions should be timely and based on evidence-
based guidelines that are tailored to individual patient preferences, 
prognoses and comorbidities
56
American 
Diabetes 
Association, 2016
B
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5.3 Patient education and self management
Recommendations Reference Grade*
All people with type 2 diabetes should be referred for structured 
diabetes patient education
42
NHMRC, 2009
A
Diabetes education should be delivered in groups or individually 42
NHMRC, 2009
A
Diabetes education should be culturally sensitive and tailored 
to the needs of socioeconomically disadvantaged populations
42
NHMRC, 2009
B
6.1 Physical activity
Recommendations Reference Grade*
People with type 2 diabetes of all ages benefit from accumulating 
30 minutes or more of moderate physical activity on most if not all 
days of the week
64
Briffa T et al, 
2006
B
Exercise and physical activity (involving aerobic and/or resistance 
exercise) should be performed on a regular basis
65
SIGN, 2014
D
6.2 Diet
Recommendations Reference Grade*
Consumption of cereal foods (especially three serves a day of 
wholegrains) is associated with reduced risk of type 2 diabetes
71
NHMRC, 2013
B
Consumption of at least one and a half serves of dairy foods (eg 
milk, yoghurt, cheese) per day is associated with reduced risk of 
type 2 diabetes
71
NHMRC, 2013
C
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6.3 Weight
Recommendations Reference Grade*
Adults with impaired fasting glucose, impaired glucose tolerance 
or diabetes can be strongly advised that the health benefits of 
5–10% weight loss include prevention, delayed progression or 
improved control of type 2 diabetes
78
NHMRC, 2013
A
For adults with body mass index (BMI) >40 kg/m2, or adults with 
BMI >35 kg/m2 and comorbidities that may improve with weight 
loss, bariatric surgery may be considered, taking into account the 
individual situation
78
NHMRC, 2013
A
Use BMI to classify overweight or obesity in adults 78
NHMRC, 2013
B
For adults, use waist circumference, in addition to BMI, to refine 
assessment of risk of obesity-related comorbidities
78
NHMRC, 2013
C
6.4 Smoking cessation
Recommendations Reference Grade*
Smoking cessation should be a major focus of the management 
of people with smoking-related diseases
86
RACGP, 2011
A
All smokers should be offered brief advice to quit smoking 86
RACGP, 2011
A
6.5 Alcohol consumption
Recommendations Reference Grade*
People with diabetes can take alcohol in moderation as part 
of a healthy lifestyle, but should aim to keep within the target 
consumption recommended for people without diabetes
65
SIGN, 2014
B
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8.1 Glycaemic monitoring
Recommendations Reference Grade*
Glycated haemoglobin (HbA1c) measurement should be used to 
assess long-term blood glucose control
96
NHMRC, 2009
A
Self-monitoring of blood glucose is recommended for patients 
with type 2 diabetes who are using insulin, where patients have 
been educated in appropriate alterations in insulin dose
(Refer to Self-monitoring of blood glucose under Section 8.2. 
Medication for examples of instances when self-monitoring of 
blood glucose  may be considered)
65
SIGN, 2014
B
Routine self-monitoring of blood glucose in people with type 2 
diabetes who are using oral glucose-lowering drugs (with the 
exception of sulphonylureas) is not recommended
65
SIGN, 2010
B
In practice
Recommendations Reference Grade*
Blood glucose control should be optimised because of its 
beneficial effects on the development and progression of 
microvascular complications
96
NHMRC, 2009
A
The potential harmful effects of optimising blood glucose control 
in people with type 2 diabetes should be considered when setting 
individual glycaemic targets
96
NHMRC, 2009
A
The general glycated haemoglobin (HbA1c) target in people with 
type 2 diabetes is ≤53 mmol/mol (≤7%). Adjustments to diabetes 
treatment should be considered when HbA1c is above this level
96
NHMRC, 2009
A
Targets for self-monitoring of blood glucose levels are 6–8 mmol/L for 
fasting and preprandial, and 6–10 mmol/L for two hour postprandial
96
NHMRC, 2009
C
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8.2.1 General medication
Recommendations Reference Grade*
Care should be taken to address the potential harmful effects 
of optimising blood glucose control when setting individual 
glycaemic targets
96
NHMRC, 2009
A
Interventions to achieve target glycated haemoglobin 
(HbA1c) should begin with lifestyle modification followed by 
pharmacological options selected on the basis of individual clinical 
circumstances, side effects and contraindications
96
NHMRC, 2009
A
Blood glucose control should be optimised because of its 
beneficial effects on the development and progression of 
microvascular complications
96
NHMRC, 2009
A
9. Managing cardiovascular disease risk
Recommendations Reference Grade*
Patients with pre-existing cardiovascular disease (CVD) are at 
high risk
149
NVDPA, 2012
A
All adults with type 2 diabetes and known prior CVD (except 
haemorrhagic stroke) should receive the maximum tolerated dose 
of a statin, irrespective of their lipid levels
Note: The maximum tolerated dose should not exceed the 
maximum available dose (eg 80 mg atorvastatin, 40 mg 
rosuvastatin)
150
Baker IDI, 2015
A
Adults with any of the following conditions do not require absolute 
CVD risk assessment using the Framingham Risk Equation 
because they are already known to be at clinically determined 
high risk of CVD:
• Diabetes and aged >60 years
• Diabetes with microalbuminuria (>20 mcg/min or urine 
albumin-to-creatinine ratio [UACR] >2.5 mg/mmol for men, 
and >3.5 mg/mmol for women)
• Moderate or severe chronic kidney disease (CKD) (persistent 
proteinuria or estimated glomerular filtration rate [eGFR] 
<45 mL/min/1.73 m2)
• A previous diagnosis of familial hypercholesterolaemia
• Systolic blood pressure ≥180 mmHg or diastolic blood 
pressure ≥110 mmHg
• Serum total cholesterol >7.5 mmol/L
149
NVDPA, 2012
D
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Calculate risk level using an evidence-based tool:
• National Vascular Disease Prevention Alliance charts, 
www.cvdcheck.org.au
• New Zealand Cardiovascular Risk charts,  
www.health.govt.nz/publications
• Heart Foundation NZ, www.knowyournumbers.co.nz
149
NVDPA, 2012
B
Aboriginal and Torres Strait Islander peoples are generally 
assumed to be at higher risk
149
NVDPA, 2012
B
Antihypertensive medication to manage 
cardiovascular risk
Recommendations Reference Grade*
Blood pressure-lowering therapy in people with diabetes should 
preferentially include an angiotensin converting enzyme inhibitor 
(ACEI) or angiotensin receptor blocker (ARB)
149
NVDPA, 2012
A
If monotherapy does not sufficiently reduce blood pressure, add 
one of the following:
• Calcium channel blocker 149
NVDPA, 2012
B
• Low-dose thiazide or thiazide-like diuretic 149
NVDPA, 2012
C
Lipid medication to manage cardiovascular risk
Recommendations Reference Grade*
Use statins as first-line therapy 149
NVDPA, 2012
A
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Antithrombotic therapy
Recommendations Reference Grade*
All adults with type 2 diabetes and known prior cardiovascular 
disease should receive long-term antiplatelet therapy unless there 
is a clear contraindication
150
Baker IDI, 2015
A
All adults with type 2 diabetes and a history of ischaemic stroke 
or transient ischaemic attack should receive:
150
Baker IDI, 2015
• low-dose aspirin, or A
• clopidogrel, or A
• combination low-dose aspirin and extended-release 
dipyridamole
B
All adults with type 2 diabetes and recent acute coronary 
syndrome and/or coronary stent should receive, for 12 months 
after the event or procedure:
150
Baker IDI, 2015
• combination low-dose aspirin and clopidogrel, or B
• combination low-dose aspirin and prasugrel, or B
• combination low-dose aspirin and ticagrelor C
All adults with type 2 diabetes and a history of coronary artery 
disease, but no acute event in the past 12 months should receive:
150
Baker IDI, 2015
• long-term low-dose aspirin, or A
• long-term clopidogrel if intolerant to aspirin B
In the presence of atrial fibrillation or other major risk factors for 
thromboembolism, there should be consideration of anticoagulant 
therapy according to other relevant guidelines
150
Baker IDI, 2015
Practice 
Point
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10.1 Diabetic retinopathy
Recommendations Reference Grade*
Ensure that all people with diabetes have a dilated fundus 
examination and visual acuity assessment at the diagnosis 
of diabetes and at least every two years
158
NHMRC, 2008
None 
provided  
(Level I 
evidence)
Examine higher risk patients (eg longer duration of diabetes, 
or poor glycaemic control, blood pressure or blood lipid control) 
without diabetic retinopathy at least annually
158
NHMRC, 2008
None 
provided  
(Level I 
evidence)
Conduct annual screening for Aboriginal or Torres Strait Islander 
peoples with diabetes
158
NHMRC, 2008
None 
provided  
(Level IV 
evidence)
10.3 Neuropathy
Diabetic peripheral neuropathy
Recommendations Reference Grade*
All patients should be screened for distal symmetric 
polyneuropathy starting at diagnosis of type 2 diabetes and 
at least annually thereafter, using simple clinical tests
19
American 
Diabetes 
Association, 2015
B
Antidepressants, including tricyclics, duloxetine and venlafaxine 
should be considered for the treatment of patients with painful 
diabetic peripheral neuropathy
65
SIGN, 2014
A
Anticonvulsants, including pregabalin and gabapentin, should 
be considered for the treatment of patients with painful diabetic 
peripheral neuropathy
65
SIGN, 2014
A
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10.4 Nephropathy
Recommendations Reference Grade*
Assessment
Kidney status in people with type 2 diabetes should be assessed 
by:
• annual screening for albuminuria (note that dipstick urine test 
is not adequate to identify albuminuria)
166
NHMRC, 2009
B
• annual estimated glomerular filtration rate (eGFR; in mL/
min/1.73 m2)
166
NHMRC, 2009
B
Management
Reducing the risk or slowing the progression of nephropathy can 
be achieved by:
• blood glucose control should be optimised aiming 
for a general glycated haemoglobin (HbA1c) target ≤7%
166
NMHRC 2009
A
• optimising blood pressure control 166
NMHRC 2009
A
In people with type 2 diabetes and microalbuminuria or 
macroalbuminuria, angiotensin receptor blocker (ARB) or 
angiotensin converting enzyme inhibitor (ACEI) antihypertensive 
should be used to protect against progression of kidney disease
166
NHMRC, 2009
A
People with type 2 diabetes should be informed that smoking 
increases the risk of chronic kidney disease
166
NHMRC, 2009
B
People with diabetes and microalbuminuria are considered 
at high cardiovascular disease risk, and should be treated 
with multifactorial interventions (refer to Chapter 9. Managing 
cardiovascular risk)
149
NVDPA, 2012
D
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10.5 Foot complications
Recommendations Reference Grade*
Assess all people with diabetes and stratify their risk of developing 
foot complications
160
NHMRC, 2011
C
Assess risk stratification by inquiring about previous foot ulceration 
and amputation plus falls risk, visually inspecting the feet for 
structural abnormalities and ulceration, assessing for neuropathy 
using either the neuropathy disability score or a 10 g monofilament 
and palpating foot
160
NHMRC, 2011
C
People assessed as having intermediate-risk or high-risk feet 
should be offered a foot protection program. This includes foot 
care education, podiatry review and appropriate footwear
160
NHMRC, 2011
C
Pressure reduction, otherwise referred to as redistribution 
of pressure or offloading, is required to optimise the healing 
of plantar foot ulcers
160
NHMRC, 2011
B
Offloading of the wound can be achieved with the use of a total 
contact cast or other device rendered irremovable
160
NHMRC, 2011
B
People with diabetes-related foot ulceration are best managed 
by a multidisciplinary foot care team
160
NHMRC, 2011
C
11. Glycaemic emergencies
Recommendations Reference Grade*
The potential harmful effects of optimising blood glucose control 
in people with diabetes should be considered when setting 
individual glycaemic targets
96
NHMRC, 2009
A
Improving blood glucose control increases the risk 
of hypoglycaemia
96
NHMRC, 2009
None 
provided 
(Level I 
evidence)
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13.2 Pregnancy with pre-existing diabetes
Recommendations Reference Grade*
Pre-pregnancy glycaemic control should be maintained as close 
to the non-diabetic range as possible, taking into account risk of 
maternal hypoglycaemia
65
SIGN, 2014
C
All women with diabetes should be prescribed *high-dose pre-
pregnancy folate supplementation, continuing up to 12 weeks’ 
gestation
65
SIGN, 2014
B
All women with pre-gestational diabetes should be encouraged 
to achieve excellent glycaemic control†
65
SIGN, 2014
D
Postprandial glucose monitoring should be carried out in pregnant 
women with type 1 or 2 diabetes
Postprandial glucose monitoring should be carried out in pregnant 
women with gestational diabetes and may be considered in 
pregnant women with type 1 or 2 diabetes
65
SIGN, 2014
C
Pre-pregnancy care provided by a multidisciplinary team 
is strongly recommended for women with diabetes
65
SIGN, 2014
C
*5 mg of folate
†Glycated haemoglobin (HbA1c) <48 mmol/mol (6.5%) and consider stabilisation using metformin 
and/or insulin to achieve glycaemic targets. However, metformin has a category C rating in 
pregnancy. Continuation or initiation of metformin therapy should be considered only following full 
disclosure to the patient and under specialist supervision. Sulphonylureas may be associated with 
adverse neonatal outcomes and are thus best avoided66,229–232
Management
Recommendations Reference Grade*
Pregnant women with gestational diabetes mellitus should be 
offered dietary advice and blood glucose monitoring, and be 
treated with glucose-lowering therapy depending on target values 
for fasting and postprandial targets
65
SIGN, 2014
A
Follow-up of patients with a history  
of gestational diabetes mellitus
Recommendations Reference Grade*
Women with a history of gestational diabetes mellitus should 
receive a postpartum oral glucose tolerance test at 6–12 weeks
19
American 
Diabetes 
Association, 2015
E
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14.1 Sick day management
Recommendations Reference Grade*
Patients should be educated to develop a sick day management 
plan after initial diagnosis. This plan should be reviewed at regular 
intervals
261
Australian 
Diabetes 
Educators 
Association, 
2014
None 
provided
Assist in the development of a sick day care plan and preparation 
of a home sick day management kit for patients to use during 
episodes of sickness
261
Australian 
Diabetes 
Educators 
Association, 
2014
None 
provided
15. Diabetes and end-of-life care
Recommendations Reference Grade*
To minimise the risks of hypoglycaemia and metabolic compensation, 
a blood glucose range of 6–15 mmol/L is appropriate for most 
palliative care patients
265
Diabetes UK,
2013
None 
provided
Maintain glycated haemoglobin (HbA1c) at no lower than 58 mmol/mol 
(7.5%) if on hypoglycaemic medication depending on the individual’s 
life expectancy, as HbA1c will be less relevant in patients with months 
or days left to live
265
Diabetes UK,
2013
None 
provided
xxxii General practice management of type 2 diabetes2016–18
Updates in this edition
Chapter
Summary of recommendations This has been moved to the front of the handbook
4. Preventing type 2 diabetes This chapter references interventions in clinical trials 
that may assist general practitioners (GPs) understand, 
and consider implementing with, patients at high risk of 
diabetes to prevent progress to type 2 diabetes
6. Lifestyle modification This chapter has been reviewed and includes some 
practical updates for GPs to implement in patients 
diagnosed with type 2 diabetes
7.  The person with diabetes – 
Assessment
Revision on practice guidelines on clinical assessment 
is included
8. Managing glycaemia The new Australian blood glucose treatment algorithm 
developed in collaboration with the Australian Diabetes 
Society is now included (Figure 4)
A table to guide clinical considerations of glucose-
lowering agents is also newly embedded (Table 6)
A revised insulin titration algorithm is included for 
premixed insulins
9. Managing cardiovascular risk Updated information on antithrombotic therapy including 
aspirin
10.  Managing microvascular and other 
complications
Expanded section on foot complications
11. Glycaemic emergencies Expanded information on the management of diabetes 
glycaemic emergencies – including Appendix J. Detailed 
information on glycaemic emergencies
13. Diabetes and reproductive health Revision of advice with emerging evidence, both in 
pregnancy with existing diabetes and gestational diabetes
16. Issues under debate Revision of blood pressure targets is discussed, based 
upon new evidence particular to diabetes
Possible new criteria for screening for diabetes in at-risk 
populations are discussed
Appendices
The following appendices from the 
2014–15 edition have been removed
Australian type 2 diabetes risk assessment tool 
(AUSDRISK)
General outline of management of hyperosmolar 
nonketotic coma from glycaemic emergencies
Potential drug interactions
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1. Introduction
Diabetes is a national health priority. The Australian National Diabetes Strategy 2016–
2020 was released by the Australian Government in November 2013. The number 
of people with type 2 diabetes is growing, most likely the result of rising overweight 
and obesity rates, lifestyle and dietary changes, and an ageing population. Within 20 
years, the number of people in Australia with type 2 diabetes may increase from an 
estimated 870,000 in 2014, to more than 2.5 million.1 The most socially disadvantaged 
Australians are twice as likely to develop diabetes.
If left undiagnosed or poorly managed, type 2 diabetes can lead to coronary artery 
disease (CAD), stroke, kidney failure, limb amputations and blindness. The early 
identification and optimal management of people with type 2 diabetes is therefore 
critical. General practice has the central role in type 2 diabetes management across 
the spectrum, from identifying those at risk right through to caring for patients at the 
end of life. These guidelines give up-to-date, evidence-based information tailored for 
general practice to support general practitioners (GPs) and their teams in providing 
high-quality management.1
In the development of the 2016–18 edition of General practice management of type 2 
diabetes, The Royal Australian College of General Practitioners (RACGP) has focused 
on factors relevant to current Australian clinical practice. The RACGP has used the 
skills and knowledge of your general practice peers who have an interest in diabetes 
management and are members of the RACGP Specific Interests Diabetes Network.
This publication has been produced in accordance with the rules and processes 
outlined in the RACGP’s conflict of interest (COI) policy. The RACGP’s COI policy is 
available at www.racgp.org.au/support/policies/organisational
This edition represents 19 years of a successful relationship between the RACGP 
and Diabetes Australia. We acknowledge the support of the RACGP Expert 
Committee – Quality Care, the Medical Education and Scientific Committee of 
Diabetes Australia, and RACGP staff in the development of these guidelines.
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General practice management of type 2 diabetes
2016–18
1.1 Defining type 2 diabetes
Diabetes is a group of disorders and the 10th leading cause of deaths in Australia. 
There are four clinical classes of diabetes:1
• Type 1 diabetes – Results from ß-cell destruction due to an autoimmune process 
usually leading to insulin deficiency
• Type 2 diabetes – Results from a progressive insulin secretory defect on the 
background of insulin resistance
• Gestational diabetes mellitus (GDM) – Defined as glucose intolerance with 
onset or first recognition during pregnancy
• Other specific types of diabetes (Section 3.3. Impaired fasting glucose or 
impaired glucose tolerance) – Due to other causes such as genetic defects in 
ß-cell function, genetic defects in insulin action, diseases of the exocrine pancreas 
(eg cystic fibrosis), and drug-induced or chemical-induced causes (eg treatment 
of human immunodeficiency virus/acquired immune deficiency syndrome [HIV/
AIDS] or after organ transplantation)
Type 2 diabetes is a largely preventable, chronic and progressive medical condition 
that results from two major metabolic dysfunctions: insulin resistance and then 
pancreatic islet cell dysfunction causing a relative insulin deficiency. In an individual, 
these occur due to modifiable lifestyle-related risk factors interacting with non-
modifiable and genetic risk factors.
The relative insulin deficiency leads to chronic hyperglycaemia and multiple 
disturbances in carbohydrate, protein and fat metabolism including:
•  ß-islet cell dysfunction, failure of response to insulin signalling and increased islet 
cell apoptosis
•  α-cell dysfunction with elevated glucagon levels
• resultant disorders of hepatic gluconeogenesis and insulin resistance with elevated 
glucose production
• muscle cell insulin resistance with decreased glucose uptake
• kidney adaptation with altered gluconeogenesis and increased glucose 
reabsorption via increased sodium glucose transporter protein activity
• diminished incretin hormonal production or resistance
• maladaptive cerebral hormonal responses to insulin and appetite
• increased lipolysis with elevated free fatty acids.
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1.2 A patient-centred approach
Throughout these guidelines we refer to patient-centred care.
The concept of patient-centred care incorporates the patient’s experience of care and 
patients as partners in their healthcare.2 In practice, this means providing care that is 
‘respectful of and responsive to individual patient preferences, needs and values, and 
ensures that patient values guide all clinical decisions’3 and supports self management.
Understanding a patient’s diabetes-related (and comorbidity) experiences can improve 
practitioner–patient communication and help the GP understand their patient’s priorities 
for education, resources and management. This is essential for building and adapting 
diabetes management plans to be consistent with an individual patient’s needs.
1.3 How to use these guidelines
These guidelines have been designed to provide pragmatic, evidence-
based recommendations for use in general practice, and adopt the most 
recent recommendations from organisations including the National Health 
and Medical Research Council (NHMRC), Scottish Intercollegiate Guidelines 
Network (SIGN), American Diabetes Association (ADA) and other relevant 
sources. The recommendations tables include the reference or source of each 
recommendation, and the grade of recommendation. In cases where these are not 
available or current, results of systematic reviews and primary research studies have 
been considered to formulate the overall recommendation. References to support 
these recommendations are included.
In each section, where possible, information is presented as:
• recommendations
• clinical context (or what you need to know)
• in practice (or what you can do).
Information specific to the Aboriginal and Torres Strait Islander population is 
highlighted in boxed text. Recommendations in some areas are different for Aboriginal 
and Torres Strait Islander patients. It is therefore important to identify, record and 
report the Aboriginal and Torres Strait Islander status of patients.
The RACGP has a position paper outlining the processes of identification, available 
at www.racgp.org.au/yourracgp/faculties/aboriginal
Refer to Summary, explanation and source of recommendations.
